Author

D. Alcalá-López

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.

PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I-IIIA opera...

J. Pérez-García, J. Cortés, M. Ruíz-Borrego et al. · Nature Medicine · 0 citations

Open access Oct 2026

Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.

CLINICAL TRIAL REGISTRATION www.clinicaltrials.gov identifier is NCT06382948; EU Clinical Trials identifier is EUCT 2024-512926-27-00.

J. Pérez-García, A. Llombart-Cussac, E. López-Miranda et al. · Future Oncology · 0 citations